Absci Corporation develops generative AI-designed biologic therapeutics as a clinical-stage biopharmaceutical company. News about ABSI centers on its Integrated Drug Creation platform, internal prolactin and prolactin receptor (PRLR) programs, and clinical development of ABS-201, an anti-PRLR antibody being developed for androgenetic alopecia and endometriosis.
Recurring updates cover HEADLINE trial safety, tolerability and pharmacokinetic disclosures, preclinical pipeline additions such as ABS-202, business and operating results, clinical advisory activity, healthcare conference participation, executive leadership changes, and Nasdaq inducement equity grants.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, has announced its participation in the 22nd Annual Needham Virtual Healthcare Conference. The management presentation is scheduled for Thursday, April 20th, at 1:30 p.m. ET (10:30 a.m. PT). Interested parties can access the live and archived webcast through the company's investor relations website.
Absci specializes in combining AI with scalable wet lab technologies to enhance drug development, aiming to accelerate time to clinic and improve success rates. Its Integrated Drug Creation™ platform allows rapid screening and validation of drug candidates. The company is headquartered in Vancouver, WA, with additional facilities in New York and Zug, Switzerland.
Absci Corporation (Nasdaq: ABSI) has partnered with M2GEN to leverage its generative AI platform and M2GEN's clinicogenomic database to accelerate the creation of new cancer treatments. This collaboration aims to streamline the drug discovery process, utilizing M2GEN's ORIEN AVATAR® data to identify specific antigens for immunotherapies. Absci's Integrated Drug Creation™ platform can reduce the time from AI-designed antibodies to lab-validated candidates to as little as six weeks. With over 360,000 patients enrolled in M2GEN's Total Cancer Care® protocol, this partnership seeks to revolutionize personalized medicine in oncology.